Allo-targeting of the kinase domain: Insights from in silico studies and comparison with experiments
- PMID: 38211377
- PMCID: PMC11044982
- DOI: 10.1016/j.sbi.2023.102770
Allo-targeting of the kinase domain: Insights from in silico studies and comparison with experiments
Abstract
The eukaryotic protein kinase domain has been a broadly explored target for drug discovery, despite limitations imposed by its high sequence conservation as a shared modular domain and the development of resistance to drugs. One way of addressing those limitations has been to target its potential allosteric sites, shortly called allo-targeting, in conjunction with, or separately from, its conserved catalytic/orthosteric site that has been widely exploited. Allosteric regulation has gained importance as an alternative to overcome the drawbacks associated with the indiscriminate effect of targeting the active site, and it turned out to be particularly useful for these highly promiscuous and broadly shared kinase domains. Yet, allo-targeting often faces challenges as the allosteric sites are not as clearly defined as its orthosteric sites, and the effect on the protein function may not be unambiguously assessed. A robust understanding of the consequence of site-specific allo-targeting on the conformational dynamics of the target protein is essential to design effective allo-targeting strategies. Recent years have seen important advances in in silico identification of druggable sites and distinguishing among them those sites expected to allosterically mediate conformational switches essential to signal transmission. The present opinion underscores the utility of such computational approaches applied to the kinase domain, with the help of comparison between computational predictions and experimental observations.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures



Similar articles
-
Computational Tools for Allosteric Drug Discovery: Site Identification and Focus Library Design.Methods Mol Biol. 2017;1529:439-446. doi: 10.1007/978-1-4939-6637-0_23. Methods Mol Biol. 2017. PMID: 27914066 Free PMC article.
-
Allo-network drugs: extension of the allosteric drug concept to protein- protein interaction and signaling networks.Curr Top Med Chem. 2013;13(1):64-77. doi: 10.2174/1568026611313010007. Curr Top Med Chem. 2013. PMID: 23409766 Review.
-
Allosteric Methods and Their Applications: Facilitating the Discovery of Allosteric Drugs and the Investigation of Allosteric Mechanisms.Acc Chem Res. 2019 Feb 19;52(2):492-500. doi: 10.1021/acs.accounts.8b00570. Epub 2019 Jan 28. Acc Chem Res. 2019. PMID: 30688063
-
Advances in the Computational Identification of Allosteric Sites and Pathways in Proteins.Adv Exp Med Biol. 2019;1163:141-169. doi: 10.1007/978-981-13-8719-7_7. Adv Exp Med Biol. 2019. PMID: 31707703 Review.
-
Assessing the structural conservation of protein pockets to study functional and allosteric sites: implications for drug discovery.BMC Struct Biol. 2010 Mar 31;10:9. doi: 10.1186/1472-6807-10-9. BMC Struct Biol. 2010. PMID: 20356358 Free PMC article.
Cited by
-
Global hinge sites of proteins as target sites for drug binding.Proc Natl Acad Sci U S A. 2024 Dec 3;121(49):e2414333121. doi: 10.1073/pnas.2414333121. Epub 2024 Nov 25. Proc Natl Acad Sci U S A. 2024. PMID: 39585988 Free PMC article.
-
Tilting the Scales toward EGFR Mutant Selectivity: Expanding the Scope of Bivalent "Type V" Kinase Inhibitors.J Med Chem. 2024 Dec 12;67(23):21438-21469. doi: 10.1021/acs.jmedchem.4c02311. Epub 2024 Dec 3. J Med Chem. 2024. PMID: 39626019 Free PMC article.
-
Advancements in Protein Kinase Inhibitors: From Discovery to Clinical Applications.Research (Wash D C). 2025 Jun 21;8:0747. doi: 10.34133/research.0747. eCollection 2025. Research (Wash D C). 2025. PMID: 40547482 Free PMC article. Review.
References
-
- Roskoski R Jr.: Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update. Pharmacol Res 2023, 187:106552. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources